At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OBIO Orchestra BioMed
Market Closed 04-17 16:00:00 EDT
2.85
-0.01
-0.35%
盘后2.85
+0.000.00%
18:50 EDT
High2.95
Low2.77
Vol41.11K
Open2.86
D1 Closing2.86
Amplitude6.26%
Mkt Cap109.19M
Tradable Cap52.40M
Total Shares38.31M
T/O116.82K
T/O Rate0.22%
Tradable Shares18.39M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Orchestra BioMed’s Strategic Advances in Medical Innovations
Orchestra Biomed Appoints Vivek Reddy, M.d. as Executive Chairman of the Backbeat Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
Orchestra Biomed Announces Data Demonstrating Favorable Impact of Avim Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, Will Be Presented as Late-Breaking Science at the Tht 2025 Conference
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.